Incidence of Headache Following an Unintentional Dural Puncture

Brief Title

Incidence of Headache Following an Unintentional Dural Puncture

Official Title

Incidence of Post-Dural Puncture Headache Following Unintentional Dural Puncture: A Randomized Trial of Intrathecal Morphine Versus Saline

Brief Summary

      The purpose of this study is to evaluate the use of intrathecal morphine administration
      following an unintentional dural puncture, to decrease the incidence of post dural puncture
      headaches (PDPH) in obstetric patients.
    

Detailed Description

      Unintentional dural puncture is a known risk of neuraxial techniques, occurring in roughly 1%
      of all epidural catheter placements. The incidence of post dural puncture headaches(PDPH)
      after unintentional dural puncture (UDP) is 50-80%. A PDPH is defined as a headache that
      occurs following a dural puncture, worsens within 15 minutes after sitting or standing and
      improves within 15 minutes after lying, with at least one of the following: neck stiffness,
      tinnitus, hypacusia, photophobia, or nausea. The headache develops within 5 days after dural
      puncture and resolves either spontaneously within 1 week or within 48 hours after effective
      treatment of the spinal fluid leak.

      The rates of PDPH following unintentional dural puncture with placement of an intrathecal
      catheter will be compared in two groups: intrathecal morphine (treatment) versus intrathecal
      saline (control) administered 1-2 hours after delivery, followed by immediate catheter
      removal. Patients randomized to the treatment group (morphine) will receive preservative-free
      morphine 0.3 mL (150 mcg) intrathecally. Those randomized to the control group will receive
      normal saline 0.3 mL intrathecally. After administration of intrathecal morphine, all
      patients will have their respirations monitored every hour for a period of 12 hours and then
      every two hours for a period of 12 hours. On postpartum days 1-5, all patients will be
      visited daily while inpatient and/or contacted by phone after discharge from the hospital.

      PDPH can lead to significant morbidity and negatively impact patient satisfaction with
      postpartum recovery. Along with headache, patients may develop cranial nerve palsy during the
      postpartum period leading to permanent disability. In addition, new mothers are unable to
      bond with their babies due to headache and associated symptoms of nausea, vomiting and
      limited mobility secondary to pain. Therefore, an effective intervention to decrease the risk
      of PDPH after UDP would be useful.
    


Study Type

Interventional


Primary Outcome

Participants Who Report Post Dural Puncture Headaches

Secondary Outcome

 Severity of Post Dural Puncture Headache

Condition

Postdural Puncture Headache

Intervention

Morphine

Study Arms / Comparison Groups

 Morphine
Description:  Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

68

Start Date

November 2011

Completion Date

March 1, 2019

Primary Completion Date

March 1, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Postpartum patients following vaginal delivery

          -  Unintentional dural puncture

          -  Functioning intrathecal catheter

          -  Patients must be 18 years of age or older

          -  English speaking.

        Exclusion Criteria:

          -  History of previous PDPH

          -  Body mass index BMI > 40 kg/m2

          -  History of obstructive sleep apnea (OSA)

          -  Morphine allergy

          -  Patients who receive Cesarean delivery
      

Gender

Female

Ages

18 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Feyce Peralta, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01977898

Organization ID

STU00043549


Responsible Party

Principal Investigator

Study Sponsor

Northwestern University


Study Sponsor

Feyce Peralta, MD, Principal Investigator, Northwestern University


Verification Date

March 2021